NVNO

Insider Trades

Name	Value	Action	Price	Current Price
Duhay FrancisDirector $1.6k140 shares SellMar 12, 2026 $11.52 --
Duhay FrancisDirector $1.7k4.9k shares SellDec 11, 2025 $0.3556 --
Duhay FrancisDirector $4.1k4.9k shares SellSep 15, 2025 $0.83 --
Duhay FrancisDirector $250k81.4k shares BuyDec 31, 2024 $3.07 --
Gray RobertDirector $10k3.5k shares BuyDec 31, 2024 $2.94 --
Shrivastava SanjayDirector $16k5.4k shares BuyDec 24, 2024 $2.90 --

News

accessnewswire.comenVVeno Medical to Participate in the Virtual Investor Closing Bell Seriesaccessnewswire.comJun 2

accessnewswire.comenVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segmentaccessnewswire.comMay 12

accessnewswire.comenVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe Systemaccessnewswire.comMay 7

accessnewswire.comenVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valveaccessnewswire.comApr 29

accessnewswire.comenVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) Systemaccessnewswire.comMar 27

Trade NVNO

About enVVeno Medical Corporation

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

CEO: Robert A. Berman
IPO Date: May 31, 2018

Market Data

Open: $10.60
High: $10.60
Low: $10.00
Volume: 12.8K
Avg Volume: 10.9K
52W High: $196.70
52W Low: $8.67

Valuation

Market Cap: $165k
Enterprise Value: $-1.8M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-16M
Revenue: $0
Net Income: $-19M
Cash: $3.1M
Debt: $700k

Events

EarningsJul 30

EPS est. -9.1